Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Other Non Operating Income (2022 - 2026)

Lexaria Bioscience's Other Non Operating Income history spans 5 years, with the latest figure at $1768.0 for Q1 2026.

  • Quarterly results put Other Non Operating Income at $1768.0 for Q1 2026, down 94.81% from a year ago — trailing twelve months through Feb 2026 was -$2193.0 (up 67.66% YoY), and the annual figure for FY2025 was -$30697.0, up 44.71%.
  • Other Non Operating Income for Q1 2026 was $1768.0 at Lexaria Bioscience, up from -$22080.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $34040.0 in Q1 2025 to a low of -$134902.0 in Q3 2023.
  • The 5-year median for Other Non Operating Income is -$7076.5 (2024), against an average of -$19685.0.
  • The sharpest move saw Other Non Operating Income tumbled 339.28% in 2024, then surged 122.89% in 2025.
  • Year by year, Other Non Operating Income stood at -$73887.0 in 2022, then soared by 37.88% to -$45896.0 in 2023, then soared by 65.31% to -$15921.0 in 2024, then plummeted by 38.68% to -$22080.0 in 2025, then soared by 108.01% to $1768.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $1768.0, -$22080.0, and $34040.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.